FDA Approval and Successful U.S. Launch
The approval of Motiva Implants on September 26 was a significant milestone, with over 250 accounts onboarded and more than 70 placing orders within three weeks. The U.S. launch is expected to generate at least $35 million in revenue in 2025.
Financial Strengthening
Accessed $25 million under the existing credit facility and completed a $50 million equity raise. Pro forma cash position at the end of the third quarter was $114 million.
Significant Cost Reductions
Operating expenses reduced by approximately $19 million in the first nine months of 2024 compared to the previous year. SG&A expenses decreased by $5.9 million, and R&D expenses declined by $2.3 million year-over-year.
Mia Femtech Expansion
Offered in 29 cities globally with 78 certified plastic surgeons. The 3-year study showed no significant complications, indicating Mia's potential to expand in the breast aesthetics market.
Improved EBITDA Performance
EBITDA loss improved to $7 million this quarter from over $16 million last year. The company is on track to achieve positive EBITDA in 2025.